United States Glucagon-like Peptide 1 (GLP-1) Analogues Market Expansion Till 2033: Eli Lilly's Mounjaro Becomes Top-Selling Weight-Loss Treatment | Most Leading Companies are Eli Lilly and Company, Novo Nordisk A/S, Hanmi Pharm. Co.., Ltd, Amgen Inc., Gm

Glucagon-like Peptide 1 (GLP-1) Analogues Market reached US$ 62.81 Billion in 2024 and is expected to reach US$ 299.08 Billion by 2033, growing at a CAGR of 17.6 % during the forecast period 2025-2033.

DataM Intelligence has released its latest report on the "Glucagon like Peptide 1 (GLP-1) Analogues Market Size 2025," providing a detailed analysis of market trends, key growth drivers, competitive landscape, and regional insights. The report includes market size (value and volume), CAGR projections, and emerging opportunities that help businesses identify growth areas and build effective strategies. Backed by data-driven insights and future outlook, this study serves as a valuable resource for companies looking to stay competitive and capitalize on market potential.

Novo Nordisk's Oral GLP-1 Pill Nears FDA Approval: A Game Changer in Obesity Care

Novo Nordisk's oral semaglutide (25 mg) from the OASIS-4 trial showed weight loss and cardiometabolic benefits on par with injectable Wegovy. After 64 weeks, 71% of patients achieved normal blood glucose versus 33% on placebo. Expected FDA approval by late 2025, this first oral GLP-1 for chronic weight management could revolutionize obesity treatment with a simple once-daily pill.

Latest M&A

Pfizer acquired Metsera in a $10 billion deal bringing clinical-stage GLP-1 (weekly and monthly) and amylin analogues indicated for obesity into Pfizer's pipeline, intensifying industry competition with Novo Nordisk and Eli Lilly.​

Novo Nordisk paid $200 million upfront for The United Laboratories' UBT251, a triple agonist (GLP-1/GIP/glucagon) candidate.​

Roche acquired Carmot Therapeutics ($2.7B, closed early 2025), gaining GLP-1/GIP combo drugs to rival industry leaders and expand its pipeline.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/glucagon-like-peptide-1-analogues-market?kb

Product Performance (October)

✦ Mounjaro: ₹100 Crore in sales, capturing 15% market share

✦ Competitor A: ₹80 Crore in sales, holding 12% market share

✦ Competitor B: ₹70 Crore in sales, accounting for 10% market share

Clinical Outcomes and Results

✦ Average Weight Loss: Achieved 10-15% reduction from baseline body weight

✦ Blood Sugar Control: Showed notable decrease in HbA1c levels

✦ Appetite Reduction: Demonstrated significant drop in hunger levels

Key Player:

Eli Lilly and Company, Novo Nordisk A/S., Sanofi, AstraZeneca, Boehringer Ingelheim, Inc., Glenmark Pharmaceuticals Ltd., Hanmi Pharm. Co.., Ltd, Amgen Inc., Gmax Biopharm., and Sciwind Biosciences Co., Ltd

Emerging Players

The emerging players in the glucagon-like peptide 1 (GLP-1) analogues market include Gmax Biopharm., Sciwind Biosciences Co., Ltd., Teva Pharmaceuticals, Inc., Hikma Pharmaceuticals PLC (Hikma), Viking Therapeutics, Terns Pharmaceuticals, Inc., Altimmune, AVVA Pharmaceuticals Ltd, LEXICARE PHARMA PVT. LTD., and Natco Pharma Limited, among others.

Key Industry Developments:

In April 2025, Meitheal Pharmaceuticals, Inc. received FDA approval for its liraglutide injection (18 mg/3 mL) and subsequently launched it in the U.S. market.

In February 2025, Biocon Limited, a leading Indian biopharmaceutical company, launched its GLP-1 peptide drug, Liraglutide, in the United Kingdom, strengthening its global footprint in diabetes and obesity care.

In January 2025, Metsera, a New York-based obesity healthcare company, reported positive Phase IIa results for MET-097i, a GLP-1 receptor agonist designed for once-monthly dosing, offering a potential advantage over more frequent treatment regimens.

In September 2024, Terns Pharmaceuticals announced positive Phase 1 trial results for TERN-601, a once-daily oral GLP-1 receptor agonist for obesity, confirming its safety, tolerability, and pharmacokinetics in overweight and obese adults.

That same month, Kourtney Kardashian expanded her Lemme wellness brand with the launch of Lemme GLP-1 Daily capsules, promoting health and nutrition through her Poosh lifestyle platform.

In August 2024, Metsera officially launched as a clinical-stage biopharmaceutical firm with US$ 290 million in funding to advance innovative GLP-1-based therapies for obesity and metabolic diseases.

In June 2024, Teva Pharmaceuticals introduced the first generic GLP-1 receptor agonist in the U.S., a liraglutide 1.8 mg formulation, marking a milestone in providing affordable diabetes treatments.

Forecast Projection:

The global Glucagon like Peptide 1 (GLP-1) Analogues market is set to witness strong growth from 2025 to 2032. After maintaining steady momentum in 2024, the market is expected to accelerate as key industry players implement strategic initiatives to boost adoption. Companies that adapt to these emerging trends will be well-positioned to capture new opportunities and enhance their revenue potential throughout the forecast period.

Latest News & Developments

Oral GLP-1s set for FDA review: Novo Nordisk's oral semaglutide 25 mg (weight loss) and oral Rybelsus for CV risk reduction are up for FDA decisions in Q4 2025.​

Teva launched first generic Saxenda® (liraglutide) for weight loss in August 2025 after FDA approval-the first generic GLP-1 for obesity, significantly improving affordability.​

GLP-1s for new indications: FDA approved Wegovy (semaglutide) for metabolic dysfunction-associated steatohepatitis (MASH) in August 2025. Ozempic's label expansions now include diabetic nephropathy and peripheral artery disease (pending). CagriSema (semaglutide/cagrilintide) and other dual/triple agonists are in late-stage trials.​

Market size: GLP-1 analogue market valued at $66.5B in 2025, projected to nearly $880B by 2034, driven by obesity and broader metabolic indication expansions.​

Price Competition & Market Trends: Zepbound's price is now $349-$499/mo; insurer and government price negotiations are shaping market dynamics, while insurers sometimes "step edit" patients to preferred products as cost sharing and utilization rise.

Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @ https://www.datamintelligence.com/buy-now-page?report=glucagon-like-peptide-1-analogues-market?kb

Key Segmentations:

By Product: Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound, Others

By Type: Long-acting GLP-1 Agonist, Short-acting GLP-1 Agonist

By Route of Administration: Subcutaneous, Oral

By Application: Type 2 Diabetes Mellitus, Obesity, Others

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/glucagon-like-peptide-1-analogues-market?kb

FAQ's

Q1: How large is the Glucagon like Peptide 1 (GLP-1) Analogues Market?

Ans: The Glucagon like Peptide 1 (GLP-1) Analogues Market size was valued at 62.81 Billion in 2024 and is projected to grow to US$ 299.08 Billion by 2033.

Q2: How quickly is the Glucagon like Peptide 1 (GLP-1) Analogues Market expanding?

Ans: The Glucagon like Peptide 1 (GLP-1) Analogues Market is forecasted to grow at a CAGR of 17.6% between 2025 and 2032, showing Annual growth momentum

Q3: Which regions are dominating the Glucagon like Peptide 1 (GLP-1) Analogues Market and which are fastest-growing?

Ans: North America dominating the Glucagon like Peptide 1 (GLP-1) Analogues market.

FDA & Regulatory Highlights

New FDA guidance (2025) makes obesity itself a qualifying indication, requiring ≥5% placebo-adjusted weight loss for approval and both trial arms to include lifestyle interventions.​

Ongoing FDA approvals/expansions for Wegovy, Ozempic, Rybelsus, and others, including for heart failure, chronic kidney disease, and fatty liver disease.​

Teva's generic liraglutide (Saxenda) is now available post FDA approval in 2025, increasing competition and price pressures

Have any Query We Will Provide in Detailed @ https://www.datamintelligence.com/enquiry/glucagon-like-peptide-1-analogues-market?kb

Reimbursement Landscape

CMS (Medicare) added Ozempic, Wegovy, and Rybelsus to its list for MFP price negotiation; negotiated prices to take effect in 2027.​

US and EU insurers now more frequently reimburse for GLP-1 drugs not only for type 2 diabetes, but also for obesity (coming 2026), heart failure, and chronic kidney disease in certain cases.​

Affordability still a concern for uninsured/underinsured and in emerging markets due to high cash price and variable private reimbursement.​

Get 2-Day Free Trial + 50% OFF DataM Subscription@ https://www.datamintelligence.com/reports-subscription?kb

Related Reports:

Weight-Loss Devices Market: https://www.datamintelligence.com/download-sample/weight-loss-devices-market?kb

Weight loss therapeutics Market: https://www.datamintelligence.com/download-sample/weight-loss-therapeutics-market?kb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
Linkedin: https://www.linkedin.com/company/datam-intelligence/
Twitter: https://x.com/DataM_Research

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.